The agent assembled a partial but substantive explanation of Affinix from the homepage and legal terms page, but could not access pricing tiers, team/company details, technical documentation, or a working view of the simulator itself—critical gaps that prevent explaining how it compares to alternatives or how a user would actually get started.

• ›The homepage and legal page were the only content-bearing fetches; they disclosed core positioning (research and teaching simulator, not clinical software), scope (1K+ drugs, 15 physiological subsystems), and strict licensing (no patient data, no AI training without license), but no pricing, team, or validation methodology.
• ›The /app simulator page returned only a title tag ('Affinix'), making it impossible to assess feature set, user interface, sign-up flow, or paywall—a critical blindspot for evaluating ease of use.
• ›/pricing returned 404, confirming pricing is either unpublished or intentionally hidden; the legal page mentions 'commercial license' without price, leaving the free/paid boundary ambiguous.
• ›The agent correctly identified that the site makes no competitive claims and offers no comparisons to pharmacometrics tools, drug-interaction checkers, or other simulators—limiting its ability to explain why someone would choose Affinix.
• ›The site is operated by a single individual (Charles Duprat, registered in France) with no visible team, company page, or funding disclosure, making organizational credibility hard to assess for a clinical tool.